206 related articles for article (PubMed ID: 33438540)
1. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
Parmar K; Shah J
Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
[TBL] [Abstract][Full Text] [Related]
2. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
Parmar K; Oza K
AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
[TBL] [Abstract][Full Text] [Related]
3. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
4. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
5. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
7. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
8. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation.
Chang D; Ma Y; Cao G; Wang J; Zhang X; Feng J; Wang W
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1018-1024. PubMed ID: 28749189
[TBL] [Abstract][Full Text] [Related]
9. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
10. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
11. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution.
Rashed M; Dadashzadeh S; Bolourchian N
Iran J Pharm Res; 2022 Dec; 21(1):e129409. PubMed ID: 36942076
[TBL] [Abstract][Full Text] [Related]
13. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
[TBL] [Abstract][Full Text] [Related]
14. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
15. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
Pınar SG; Canpınar H; Tan Ç; Çelebi N
Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012
[TBL] [Abstract][Full Text] [Related]
16.
Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
[TBL] [Abstract][Full Text] [Related]
17. Surface Engineering of Fenofibrate Nanocrystals Using Nano-by-Design Multivariate Integration: A Biopharmaceutical and Pharmacokinetic Perspective.
Gite S; Kakade P; Patravale V
Curr Drug Deliv; 2021; 18(9):1314-1329. PubMed ID: 33655832
[TBL] [Abstract][Full Text] [Related]
18. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
19. Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability.
Rahim H; Sadiq A; Ullah R; Bari A; Amin F; Farooq U; Ullah Jan N; Mahmood HM
Int J Nanomedicine; 2020; 15():8999-9009. PubMed ID: 33235448
[TBL] [Abstract][Full Text] [Related]
20. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
